文献速递癫痫认知障碍与痴呆

氨己烯酸早期治疗不减少结节性硬化症局灶性发作也不改善认知:PREVeNT试验

Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial.
PubMed 文献 · Ann Neurol · 2023-09-25

这项IIb期多中心随机双盲安慰剂对照试验在结节性硬化症(TSC)婴儿中比较首次脑电图癫痫样放电即开始氨己烯酸与发作时开始氨己烯酸。主要结局24月龄Bayley-III认知评分两组相似;氨己烯酸组婴儿痉挛发生率更低且发作时间更晚,但局灶性发作和药物难治性癫痫无差异。

要点

  • 基于脑电图癫痫样放电的预防性氨己烯酸未改善24月龄认知结局。
  • 氨己烯酸组婴儿痉挛发生率更低且随机化后至痉挛时间更晚。
  • 总体癫痫发生率、药物难治性癫痫及首次发作时间两组无显著差异。

核心结论

  • 在结节性硬化症(TSC)儿童中,基于发作前脑电图癫痫样活动的预防性氨己烯酸治疗不改善24月龄神经认知结局,也不延迟或降低局灶性发作和药物难治性癫痫的发生率。
  • 预防性氨己烯酸与婴儿痉挛发生时间更晚和发生率更低相关。

研究设计与样本

  • IIb期多中心随机双盲安慰剂对照试验,比较首次脑电图癫痫样放电即开始氨己烯酸与发作时开始氨己烯酸。
  • 84例TSC婴儿入组,12例筛选失败,4例直接开放标签氨己烯酸,12例未随机化(全程脑电图正常),56例随机至早期氨己烯酸组(n=29)或安慰剂组(n=27)。
  • 主要结局为24月龄Bayley婴幼儿发展量表第三版(Bayley-III)认知评估评分;次要结局包括药物难治性癫痫患病率、其他发育结局和氨己烯酸安全性。

主要发现

  • 随机至氨己烯酸或安慰剂的受试者24月龄Bayley-III认知综合评分相似。
  • 24月龄时总体癫痫发生率、药物难治性癫痫、随机化后至首次发作时间及次要发育结局两组间均无显著差异。
  • 氨己烯酸组婴儿痉挛发生率更低,随机化后至痉挛时间更晚。
  • 不良事件两组相似。
  • 安慰剂组27例中19例转为开放标签氨己烯酸,随机化后中位延迟44天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to test the hypothesis that early vigabatrin treatment in tuberous sclerosis complex (TSC) infants improves neurocognitive outcome at 24 months of age. METHODS: A phase IIb multicenter randomized double-blind placebo-controlled trial was conducted of vigabatrin at first epileptiform electroencephalogram (EEG) versus vigabatrin at seizure onset in infants with TSC. Primary outcome was Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) cognitive assessment score at 24 months. Secondary outcomes were prevalence of drug-resistant epilepsy, additional developmental outcomes, and safety of vigabatrin. RESULTS: Of 84 infants enrolled, 12 were screen failures, 4 went straight to open label vigabatrin, and 12 were not randomized (normal EEG throughout). Fifty-six were randomized to early vigabatrin (n = 29) or placebo (n = 27). Nineteen of 27 in the placebo arm transitioned to open label vigabatrin, with a median delay of 44 days after randomization. Bayley-III cognitive composite scores at 24 months were similar for participants randomized to vigabatrin or placebo. Additionally, no significant differences were found between groups in overall epilepsy incidence and drug-resistant epilepsy at 24 months, time to first seizure after randomization, and secondary developmental outcomes. Incidence of infantile spasms was lower and time to spasms after randomization was later in the vigabatrin group. Adverse events were similar across groups. INTERPRETATION: Preventative treatment with vigabatrin based on EEG epileptiform activity prior to seizure onset does not improve neurocognitive outcome at 24 months in TSC children, nor does it delay onset or lower the incidence of focal seizures and drug-resistant epilepsy at 24 months. Preventative vigabatrin was associated with later time to onset and lower incidence of infantile spasms. ANN NEUROL 2024;95:15-26.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Bebin EM, Peters JM, Porter BE, et al. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial. Ann Neurol. 2023. PMID: 37638552. doi:10.1002/ana.26778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。